CorMedix (CRMD) Amortization of Deferred Charges (2012 - 2025)
CorMedix (CRMD) posted Amortization of Deferred Charges of $255616.0 for Q4 2025, up 147.36% sequentially from $103339.0 in Q3 2025, and up 562.49% YoY from $38584.0 in Q4 2024.
CorMedix (CRMD) Amortization of Deferred Charges (2012 - 2025) Analysis & Trends
CorMedix has reported Amortization of Deferred Charges for 8 years, with the latest figure at $255616.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 562.49% year-over-year to $255616.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $438000.0 (up 195.95% YoY) and the FY2025 annual result came in at $438000.0, up 195.95% from the prior year.
- Amortization of Deferred Charges climbed to $255616.0 in Q4 2025 per CRMD's latest filing, from $103339.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $255616.0 in Q4 2025 and troughed at $27878.0 in Q1 2021.
- A 5-year average of $48017.8 and a median of $33694.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2025: Amortization of Deferred Charges climbed 7.21% in 2022, then soared 562.49% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $29701.0 in 2021, then advanced by 7.27% to $31861.0 in 2022, then rose by 9.34% to $34837.0 in 2023, then advanced by 10.76% to $38584.0 in 2024, then jumped by 562.49% to $255616.0 in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $255616.0, $103339.0, and $39981.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 255,616.00 |
| Dec 31, 2025 | 255,616.00 |
| Sep 30, 2025 | 103,339.00 |
| Sep 30, 2025 | 103,339.00 |
| Jun 30, 2025 | 39,981.00 |
| Jun 30, 2025 | 39,981.00 |
| Mar 31, 2025 | 39,064.00 |
| Mar 31, 2025 | 39,064.00 |
| Dec 31, 2024 | 38,584.00 |
| Dec 31, 2024 | 38,584.00 |
| Sep 30, 2024 | 37,306.00 |
| Sep 30, 2024 | 37,306.00 |
| Jun 30, 2024 | 36,466.00 |
| Jun 30, 2024 | 36,466.00 |
| Mar 31, 2024 | 35,644.00 |
| Mar 31, 2024 | 35,644.00 |
| Dec 31, 2023 | 34,837.00 |
| Dec 31, 2023 | 34,837.00 |
| Sep 30, 2023 | 34,069.00 |
| Sep 30, 2023 | 34,069.00 |